Non-Small Cell Lung Cancer (NSCLC)

Developers intend to submit a supplemental new drug application for toripalimab/chemotherapy in resectable stage II or III NSCLC.

Approval of the FoundationOne CDx may help identify patients with NSCLC harboring MET exon 14 skipping alterations who are candidates for tepotinib.

Disease control was observed in all patients who received JNJ-1900 in part 1 of the phase 2 CONVERGE trial.

Data from the phase 1/2 SOHO-01 study support the supplemental new drug application for sevabertinib in this NSCLC population.

The safety profile of zoldonrasib appeared to be “superb” among patients with NSCLC harboring KRAS G12D mutations, said Jonathan Wesley Riess, MD, MS.

The FDA has set a Prescription Drug User Fee Act date of January 4, 2027, for approving taletrectinib in this ROS1-positive NSCLC population.

Updated findings from the TRUST-I and TRUST-II trials may reflect the importance of molecular testing in non–small cell lung cancer therapy.

Previous data presented at the 2026 AACR Annual Meeting demonstrate the efficacy of taletrectinib in ROS1-positive NSCLC harboring brain metastases.

Preliminary data from the phase 1/1b RMC-9805-001 study support continued development of zoldonrasib as a therapeutic strategy in this population.

Data from the phase 2 MATISSE trial could pave the way for CD39 and adenosine pathway inhibition in early-stage non–small cell lung cancer.

A numerical survival improvement was observed with ramucirumab plus pembrolizumab among those with squamous cell carcinoma in a phase 2 study.

Experts discussed the evolving landscape of EGFR-mutated NSCLC, focusing on the practice-changing results of the ADAURA and NeoADAURA trials.

Data from the Beamion LUNG-1 trial may help clinicians make informed decisions on HER2-targeted therapy for those with advanced or metastatic NSCLC.

All injections of JNJ-1900 have been completed according to plan so far in the phase 2 CONVERGE study, said Benjamin Cooper, MD.

Data from the PRESERVE-003 trial may support the use of a novel chemotherapy-free option for patients with squamous non–small cell lung cancer.

Data from the phase 1/2 ALKOVE-1 trial support the application for neladalkib in this non–small cell lung cancer population.

Data from the PALOMA-2 trial showed comparable efficacy with subcutaneous amivantamab vs prior reports of the intravenous formulation.

Patients with stage IIA to IIIA NSCLC identified as low risk per LAMPAD criteria may be candidates for treatment de-escalation with nivolumab.

Data from a phase 1 study may support combining KRAS inhibition with immune checkpoint inhibition in this NSCLC population.

Data from the phase 3 TOP trial support a potential molecular risk–guided treatment strategy for EGFR-mutant advanced NSCLC.

Low-grade toxicity related to durvalumab in the ASTEROID trial was common, which mostly consisted of skin reactions, pruritus, and fatigue.

Investigators are currently evaluating treatment with TRI-611 among patients with ALK-positive non–small cell lung cancer in a phase 1/2 trial.

Data from the SAMSON-II trial showed comparable PFS and OS outcomes with HD204 and reference bevacizumab among patients with nonsquamous NSCLC.

Treatment with sunvozertinib showed improvement across all secondary end points among those with EGFR exon 20 insertion mutation–positive NSCLC.

Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1–positive subgroups, suggesting biomarker-driven therapeutic selection.